Pennsylvania-baserade JBS Science sa idag att de fick Bridge Award på 3 miljoner dollar för småföretagsinnovationsforskning IIB från National Cancer Institute. Företaget utvecklade den första flytande biopsiprodukten, som är urin-DNA-screening för tidig levercellscancer (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of lever cancer. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumör DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS sade att det har samarbetat med James Hamilton från Johns Hopkins University Medical Center och Hie-Won Hann från Thomas University Hospital för att främja utvecklingen av urintest för levercancer.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
